On October 19, 2026, H.C. Wainwright reiterated its Buy rating and $25.00 price target for CervoMed Inc. The reaffirmation followed the company’s presentation of positive initial data from its Phase 2a trial of neflamapimod, a treatment for a rare neurodegenerative disorder.
Presented at a medical conference, the data showed positive effects on a key biomarker related to neurodegeneration. H.C. Wainwright’s $25.00 target is significantly above CervoMed’s current stock price. As a clinical-stage company, CervoMed’s valuation depends heavily on trial outcomes and the program’s future potential.